News coverage about Can Fite Biopharma (NASDAQ:CANF) has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Can Fite Biopharma earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.1615875794168 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Can Fite Biopharma (CANF) opened at 1.58 on Wednesday. The company has a 50-day moving average of $1.75 and a 200-day moving average of $1.84. The stock’s market capitalization is $24.49 million. Can Fite Biopharma has a 12 month low of $1.50 and a 12 month high of $2.82.

A number of brokerages recently weighed in on CANF. Maxim Group began coverage on shares of Can Fite Biopharma in a research report on Friday, August 11th. They issued a “buy” rating and a $7.00 price target for the company. HC Wainwright set a $6.00 price target on shares of Can Fite Biopharma and gave the company a “buy” rating in a research report on Thursday, August 10th.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-can-fite-biopharma-canf-stock-price/1492865.html.

Can Fite Biopharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.